Pharmaceutical firms get cold feet about potential OTC switches when they consider the costs for studies to update safety data for an ingredient, suggests Laura Mahecha, a health care market consultant for research firm Kline & Co.
During a June 27 webinar, “Key Issues Trending in the US OTC Market,” Mahecha noted that with safety "paramount for switch approval," data from a drug ingredient's initial